

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000  
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent  
number searching  
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing  
enhanced  
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT  
Applications  
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of  
pre-registered REACH substances  
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts  
availability of new fully-indexed citations  
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 12 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
NEWS 14 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
NEWS 16 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 17 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 11:52:13 ON 13 JAN 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 11:52:28 ON 13 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JAN 2009 HIGHEST RN 1093343-19-1

DICTIONARY FILE UPDATES: 12 JAN 2009 HIGHEST RN 1093343-19-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10587792.str



```

chain nodes :
7 8 12 19 22 23 24 41 56
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 25 26 27 28 29 30 31 32 33 34
35 36 37 38 39 40 42 43 44 45 46 47 48 49 50 51
chain bonds :
1-8 4-7 5-22 12-13 17-19 22-23 23-24 24-56 36-41
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 25-26 25-
30
26-27 27-28 28-29 29-30 29-31 30-34 31-32 32-33 33-34 35-36 35-40 36-37
37-38 38-39
39-40 42-43 42-47 43-44 44-45 45-46 46-47 46-48 47-51 48-49 49-50 50-51
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-22 12-13 17-19 22-23 23-24 24-56
36-41 42-43 42-47 43-44 44-45 45-46
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18 25-26 25-30 26-27 27-28 28-29 29-30
29-31 30-34 31-32 32-33 33-34 35-36 35-40 36-37 37-38 38-39 39-40 46-47
46-48 47-51
48-49 49-50 50-51
isolated ring systems :
containing 13 : 25 : 35 : 42 :

```

G1:S,N

G2:Ak, [\*1]

G3:[\*2],[\*3],[\*4]

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 22:CLASS 23:CLASS 24:CLASS
25:Atom 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom
36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:CLASS 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom
47:Atom
48:Atom 49:Atom 50:Atom 51:Atom 56:CLASS

```

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.48

0.70

FILE 'CAPLUS' ENTERED AT 11:52:55 ON 13 JAN 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2009 VOL 150 ISS 3  
FILE LAST UPDATED: 12 Jan 2009 (20090112/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l1 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:53:05 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 706788 TO ITERATE

98.6% PROCESSED 696979 ITERATIONS 636 ANSWERS

100.0% PROCESSED 706788 ITERATIONS 636 ANSWERS  
SEARCH TIME: 00.00.20

L2 636 SEA SSS FUL L1

L3 6 L2

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2008:157019 CAPLUS Full-text  
DOCUMENT NUMBER: 148:239201

TITLE: Preparation of imidazole or thiazole derivatives for treatment of pain or migraine  
INVENTOR(S): Stoehr, Thomas; Rodriguez, Maria Luz Lopez; Salama, Bellinda Benhamu

PATENT ASSIGNEE(S): Schwarz Pharma S.L., Spain  
 SOURCE: PCT Int. Appl., 75pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2008015538 | A2   | 20080207 | WO 2007-IB2194  | 20070731 |
| WO 2008015538 | A3   | 20080515 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-834384P P 20060731  
 US 2006-834385P P 20060731

OTHER SOURCE(S): MARPAT 148:239201  
 GI



AB The title compds. with general formula I [wherein R1 = H, -(CH2)3-, -(CH2)4-, -CH2SCH2-, or -SCH2CH2-; R2 = N or S; R3 = H, C1-C10 alkyl, aryl, or arylalkyl; R4 = O or CH2; R5 = (un)substituted Ph, naphthyl, pyridinyl, furanyl, etc.; Z = C2-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; n = 0-1; m = 0-2] or pharmaceutically acceptable isomers, hydrates, solvates, or salts thereof were prepared for preventing or treating pain or migraine in a subject. General synthesis of I was discussed in the present invention with IR and NMR data reported. Compound II showed analgesic activities in formalin pain assay on male mouse with > 75% pain reduction in late phase, when administered by i.p. injection at 10 mg/kg.


IT 658714-55-7P 658714-57-9P 658714-58-0P  
 658714-60-4P 658714-66-0P 658714-67-1P  
 658714-76-2P 658714-78-4P 658714-79-5P  
 658714-80-8P 658714-81-9P 658714-88-6P  
 793666-55-4P 862589-93-3P 862589-94-4P  
 862589-96-6P 862589-98-9P 862590-00-9P  
 862590-02-1P 862590-04-3P 862590-06-5P  
 862590-07-6P 862590-10-1P 862590-11-2P  
 862590-13-4P 862590-15-6P 862590-17-8P  
 862590-18-9P 862590-20-3P 862590-21-4P  
 862590-23-6P 862590-25-8P 862590-28-1P  
 862590-30-5P 862590-32-7P 862590-33-8P  
 862590-34-9P 862590-35-0P 862590-37-2P  
 862590-38-3P 862590-39-4P 862590-40-7P  
 862590-41-8P 862590-42-9P 862590-43-0P  
 862590-44-1P 862590-45-2P 862590-46-3P  
 862590-47-4P 862590-48-5P 862590-49-6P  
 862590-50-9P 862590-51-0P 862590-52-1P  
 862590-53-2P 862590-54-3P 862590-57-6P  
 862590-58-7P 862590-59-8P 862590-60-1P  
 862590-61-2P 862590-62-3P 862590-63-4P  
 862590-64-5P 862590-65-6P 862590-66-7P  
 862590-67-8P 862590-68-9P 862590-69-0P  
 862590-70-3P 862590-71-4P 862590-72-5P  
 862590-73-6P 862590-74-7P 862590-75-8P  
 862590-76-9P 862590-77-0P 862590-78-1P  
 862591-00-2P 862645-79-2P 1005741-13-8P  
 1005741-16-1P 1005741-19-4P 1005741-24-1P  
 1005741-25-2P 1005741-26-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of imidazole or thiazole derivs. for treatment  
 of pain or migraine)


RN 658714-55-7 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-  
 (CA INDEX NAME)]




RN 658714-57-9 CAPLUS

CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione,  
 6-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX  
 NAME)]




RN 658714-58-0 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX NAME)




RN 658714-60-4 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]- (CA INDEX NAME)




RN 658714-66-0 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)




RN 658714-67-1 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)



RN 658714-76-2 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-78-4 CAPLUS


CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione,  
6-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-79-5 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl



RN 658714-80-8 CAPLUS


CN 2,4-Thiazolidinedione, 3-[5-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-81-9 CAPLUS


CN 2,4-Thiazolidinedione, 3-[6-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-88-6 CAPLUS


CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 793666-55-4 CAPLUS

CN 2,4-Thiazolidinedione, 3-[5-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]- (CA INDEX NAME)




RN 862589-93-3 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]  
 methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 862589-94-4 CAPLUS  
 CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-,  
 hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862589-96-6 CAPLUS  
 CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862589-98-8 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[5-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-00-9 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[6-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-02-1 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-04-3 CAPLUS

CN 2,4-Thiazolidinedione, 3-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-06-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 862590-07-6 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]tetrahydro-  
(CA INDEX NAME)



RN 862590-10-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[(2E)-4-[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-  
yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 862590-11-2 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-13-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-15-6 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-17-8 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-18-9 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-20-3 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-21-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(1-methylethyl)phenoxy]ethyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862590-23-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)




RN 862590-25-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-28-1 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-30-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-32-7 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-[[1,1'-biphenyl]-2-yloxy]ethyl]amino]butyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)






● HCl

RN 862590-33-8 CAPLUS


CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-34-9 CAPLUS


CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862590-35-0 CAPLUS

CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-37-2 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[4-[[2-(2,3-dimethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
 (1:1) (CA INDEX NAME)



● HCl


RN 862590-38-3 CAPLUS  
 CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione,  
 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-,  
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-39-4 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[(2Z)-4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 862590-40-7 CAPLUS


CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-41-8 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-42-9 CAPLUS


CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]-, hydrochloride (1:1) (CA INDEX NAME)

hydrochloride (1:1) (CA INDEX NAME)




RN 862590-43-0 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)




RN 862590-44-1 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



RN 862590-45-2 CAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]-, hydrochloride (1:2)  
(CA INDEX NAME)



●2 HCl

RN 862590-46-3 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]-, hydrochloride (1:2)  
(CA INDEX NAME)




●2 HCl

RN 862590-47-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]  
methyl]amino]butyl]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 862590-48-5 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-  
(CA INDEX NAME)




RN 862590-49-6 CAPLUS

CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro- (CA INDEX NAME)




RN 862590-50-9 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[5-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro- (CA INDEX NAME)




RN 862590-51-0 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[6-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro- (CA INDEX NAME)




RN 862590-52-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro- (CA INDEX NAME)



RN 862590-53-2 CAPLUS


CN 2,4-Thiazolidinedione, 3-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]- (CA INDEX NAME)



RN 862590-54-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 862590-57-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2E)-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)


Double bond geometry as shown.



RN 862590-58-7 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,

tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-59-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-60-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-61-2 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-62-3 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)






RN 862590-63-4 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-64-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-65-6 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-66-7 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-([1,1'-biphenyl]-2-yl)oxy]ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)






RN 862590-71-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[[2Z)-4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 862590-72-5 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-73-6 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]- (CA INDEX NAME)




RN 862590-74-7 CAPLUS

CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]- (CA INDEX NAME)




RN 862590-75-8 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-76-9 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro- (CA INDEX NAME)




RN 862590-77-0 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)




RN 862590-78-1 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]- (CA INDEX NAME)




RN 862591-00-2 CAPLUS

CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester (CA INDEX NAME)




RN 862645-79-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[2-(1-methylethyl)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)




RN 1005741-13-8 CAPLUS

CN Imidazo[5,1-b]thiazole-5,7(6H,7aH)-dione,  
6-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro-  
INDEX NAME) (CA



RN 1005741-16-1 CAPLUS


CN Imidazo[5,1-b]thiazole-5,7(6H,7aH)-dione,  
6-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1005741-19-4 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]-, hydrochloride (1:1) (CA  
INDEX NAME)




● HCl

RN 1005741-24-1 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]tetrahydro-,  
 hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 1005741-25-2 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 tetrahydro-2-[4-[[2-(quinolinylmethyl)amino]butyl]-, hydrochloride (1:1)  
 (CA INDEX NAME)



● HCl

RN 1005741-26-3 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
 (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:400379 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 148:262581  
 TITLE: A novel process to prepare rosiglitazone maleate  
 INVENTOR(S): Bipin, Pandey; Bhushan, Lohray Braj; Bhushan, Lohray  
 Vidya

PATENT ASSIGNEE(S): Cadila Healthcare Limited, India  
 SOURCE: Indian Pat. Appl., 35pp.  
 CODEN: INXXBQ  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.     | KIND | DATE     | APPLICATION NO. | DATE        |
|----------------|------|----------|-----------------|-------------|
| IN 2004MU00004 | A    | 20060929 | IN 2004-MU4     | 20040102    |
| IN 2007MU00411 | A    | 20081114 | IN 2007-MU411   | 20070305    |
|                |      |          | IN 2004-MU4     | A3 20040102 |

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 148:262581


AB The invention relates to process for the preparation of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4- dione, maleate namely Rosiglitazone maleate through intermediates. Rosiglitazone was prepared by reductive alkylation of 2-aminopyridine with formaldehyde and 5,5-dimethylhydantoin; the resulting 5,5-dimethyl-3-(pyridin-2-ylaminomethyl)imidazolidine-2,4-dione underwent reductive alkylation of 4-(2-bromoethoxy)benzaldehyde to give 4-[2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)ethoxy]benzaldehyde, which underwent condensation with thiazolidine-2,4-dione to give the corresponding benzylidenethiazolidinedione derivative, which underwent hydrogenation to give the corresponding benzylthiazolidinedione derivs, which underwent reduction to give rosiglitazone, which was added maleic acid to obtain rosiglitazone maleic acid salt.

IT 1006684-61-2P 1006684-62-3F 1006684-63-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (a process to prepare rosiglitazone maleate)

RN 1006684-61-2 CAPLUS


CN Benzaldehyde, 4-[2-[[4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-2-pyridinylamino]ethoxy]- (CA INDEX NAME)




RN 1006684-62-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-[[4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-2-pyridinylamino]ethoxy]phenyl)methylene]- (CA INDEX NAME)





RN 1006684-63-4 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-[[[(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-2-pyridinylamino]ethoxy]phenyl]methyl]- (CA INDEX NAME)





L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:823710 CAPLUS Full-text  
 DOCUMENT NUMBER: 143:229856  
 TITLE: Preparation of diaza- or thiazadione derivatives as modulators of 5-HT1A receptor  
 INVENTOR(S): Lopez Rodriguez, Maria Luz; Benhamu Salama, Bellinda; Del Rio Zambrana, Joaquin; Frechilla Manso, Diana; Marco Martinez, Isabel  
 PATENT ASSIGNEE(S): Cepa Schwarz Pharma S.L., Spain  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.     | KIND   | DATE     | APPLICATION NO.  | DATE     |
|----------------|--|----------|------------------|----------|
| WO 2005075480  | A1   | 20050818 | WO 2005-EP840    | 20050128 |
| W:             | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                  |          |
| RW:            | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                  |          |
| ES 2238015     | A1   | 20050801 | ES 2004-205      | 20040130 |
| ES 2238015     | B1   | 20061101 |                  |          |
| AU 2005211486  | A1   | 20050818 | AU 2005-211486   | 20050128 |
| CA 2554217     | A1   | 20050818 | CA 2005-2554217  | 20050128 |
| EP 1711500     | A1   | 20061018 | EP 2005-707057   | 20050128 |
| R:             | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU   |          |                  |          |
| BR 2005006495  | A  | 20070213 | BR 2005-6495     | 20050128 |
| CN 1914209     | A  | 20070214 | CN 2005-80003594 | 20050128 |
| JP 2007519679  | T  | 20070719 | JP 2006-550114   | 20050128 |
| MX 2006PA08532 | A  | 20070125 | MX 2006-PA8532   | 20060728 |
| NO 2006003857  | A  | 20061026 | NO 2006-3857     | 20060829 |
| KR 2006134089  | A  | 20061227 | KR 2006-717434   | 20060829 |


US 20080200470  
PRIORITY APPLN. INFO.:

A1 20080821  
MARPAT 143:229856


US 2007-587792  
ES 2004-205  
WO 2005-EP840

20070816  
A 20040130  
W 20050128

OTHER SOURCE(S):  
GI



I



II

AB Title compds. I [R1 and R2 independently = H or together form 5-6 membered heterocyclic ring, if Y = S then R1 = H and R2 is absent; Y = N or S; W = (CH2)n; n = 0-1; Z = (CH2)m; m = 1-2; X = alkyl, alkenyl or -CH2-phenyl-CH2-; R3 = (un)substituted chroman-2-yl, 2-quinolyl or -O-Ph with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of 5-HT1A receptor. Thus, e.g., II was prepared by substitution of the corresponding alkylamine with the resp. halogenated derivative The activity of I was evaluated in radioligand binding assays towards the 5-HT1A receptor and it was revealed that compds. of the invention displayed Ki values in the range of 0.5 up to 100 nM. I as modulator of 5-HT1A receptor should prove useful as treatment of Parkinson's disease, depression and migraine. Pharmaceutical compns. comprising I are disclosed.

II 862589-93-3P 862589-94-4P 862589-96-6P  
862589-98-8P 862590-00-9P 862590-02-1P  
862590-04-3P 862590-06-5P 862590-07-6P  
862590-10-1P 862590-11-2P 862590-13-4P  
862590-15-6P 862590-17-8P 862590-18-9P  
862590-20-3P 862590-21-4P 862590-23-6P  
862590-25-8P 862590-26-1P 862590-30-5P  
862590-32-7P 862590-33-8P 862590-34-9P  
862590-35-0P 862590-37-2P 862590-38-3P  
862590-39-4P 862590-40-7P 862590-41-8P  
862590-42-9P 862590-43-0P 862590-44-1P  
862590-45-2P 862590-46-3P 862590-47-4P  
862590-48-5P 862590-49-6P 862590-50-9P  
862590-51-0P 862590-52-1P 862590-53-2P  
862590-54-3P 862590-57-6P 862590-58-7P  
862590-59-8P 862590-60-1P 862590-61-2P  
862590-62-3P 862590-63-4P 862590-64-5P  
862590-65-6P 862590-66-7P 862590-67-8P

862590-66-9P 862590-69-0P 862590-70-3P  
 862590-71-4P 862590-72-5P 862590-73-6P  
 862590-74-7P 862590-75-8P 862590-76-9P  
 862590-77-0P 862590-78-1P 862591-00-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of diaza- or thiazadione derivs. as modulators of 5-HT1A  
 receptor)

RN 862589-93-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-  
 yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 862589-94-4 CAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-,  
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862589-96-6 CAPLUS


CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-  
 yl)methyl]amino]butyl]hexahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862589-98-8 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[5-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-00-9 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[6-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-02-1 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-04-3 CAPLUS

CN 2,4-Thiazolidinedione, 3-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-06-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 862590-07-6 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-10-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[(2E)-4-[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-  
yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 862590-11-2 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-13-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-15-6 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-17-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)




● HCl

RN 862590-18-9 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)






● HCl

RN 862590-20-3 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



● HCl

RN 862590-21-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(1-methylethyl)phenoxy]ethyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862590-23-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)




RN 862590-25-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-28-1 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-30-5 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-32-7 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-[[1,1'-biphenyl]-2-yloxy]ethyl]amino]butyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-33-8 CAPLUS


CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-34-9 CAPLUS


CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862590-35-0 CAPLUS

CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-37-2 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[4-[[2-(2,3-dimethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
 (1:1) (CA INDEX NAME)



● HCl


RN 862590-38-3 CAPLUS  
 CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione,  
 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-,  
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-39-4 CAPLUS  
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
 2-[(2Z)-4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 862590-40-7 CAPLUS


CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-41-8 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862590-42-9 CAPLUS


CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]-, hydrochloride (1:1) (CA INDEX NAME)

hydrochloride (1:1) (CA INDEX NAME)




RN 862590-43-0 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)




RN 862590-44-1 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro-, hydrochloride  
(1:1) (CA INDEX NAME)



RN 862590-45-2 CAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]-, hydrochloride (1:2)  
(CA INDEX NAME)



●2 HCl

RN 862590-46-3 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]-, hydrochloride (1:2)  
(CA INDEX NAME)




●2 HCl

RN 862590-47-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]  
methyl]amino]butyl]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 862590-48-5 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-  
(CA INDEX NAME)




RN 862590-49-6 CAPLUS

CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro- (CA INDEX NAME)




RN 862590-50-9 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[5-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro- (CA INDEX NAME)



RN 862590-51-0 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[6-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro- (CA INDEX NAME)



RN 862590-52-1 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro- (CA INDEX NAME)





RN 862590-53-2 CAPLUS


CN 2,4-Thiazolidinedione, 3-[8-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]- (CA INDEX NAME)



RN 862590-54-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 862590-57-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[[[(2E)-4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)


Double bond geometry as shown.



RN 862590-58-7 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,

tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-59-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-60-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-61-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-62-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-63-4 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-64-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-65-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-66-7 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[2-([1,1'-biphenyl]-2-yl)oxy]ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-67-8 CAPLUS

CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 862590-68-9 CAPLUS

CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 862590-69-0 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-70-3 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione, 2-[4-[[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-71-4 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[[2Z)-4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 862590-72-5 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)




RN 862590-73-6 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]- (CA INDEX NAME)




RN 862590-74-7 CAPLUS

CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]- (CA INDEX NAME)




RN 862590-75-8 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)




RN 862590-76-9 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro- (CA INDEX NAME)




RN 862590-77-0 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)




RN 862590-78-1 CAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,  
tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]- (CA INDEX NAME)



RN 862591-00-2 CAPLUS

CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:143157 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:181451

TITLE: Preparation of fused heterocycles as 5-HT1A receptor agonists

INVENTOR(S): Del Rio, Zambrana Joaquin; Frechilla Manso, Diana; Lopez Rodriguez, Luz M.; Benhamu Salama, Bellinda; Fuentes Cubero, Jose Angel; Delgado Wallace, Mercedes

PATENT ASSIGNEE(S): Cepa Schwarz Pharma S.L., Spain

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO.  | KIND | DATE              | APPLICATION NO.  | DATE        |
|---|------|-------------------|------------------|-------------|
| WO 2004014915   | A1   | 20040219          | WO 2003-ES394    | 20030729    |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW |      |                   |                  |             |
| RW: GH, GM, KE, LS, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |                   |                  |             |
| ES 2199086  | A1   | 20040201          | ES 2002-1811     | 20020731    |
| ES 2199086  | B1   | 20050601          |                  |             |
| CA 2492837  | A1   | 20040219          | CA 2003-2492837  | 20030729    |
| AU 2003254512   | A1   | 20040225          | AU 2003-254512   | 20030729    |
| BR 2003013375   | A    | 20050621          | BR 2003-13375    | 20030729    |
| EP 1544201  | A1   | 20050622          | EP 2003-784210   | 20030729    |
| EP 1544201  | B1   | 20060628          |                  |             |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |                   |                  |             |
| CN 1671708  | A    | 20050921          | CN 2003-818339   | 20030729    |
| JP 2005539017   | T    | 20051222          | JP 2004-526925   | 20030729    |
| AT 331717   | T    | 20060715          | AT 2003-784210   | 20030729    |
| NZ 538489   | A    | 20060929          | NZ 2003-538489   | 20030729    |
| ES 2271673  | T3   | 20070416          | ES 2003-784210   | 20030729    |
| RU 2322445  | C2   | 20080420          | RU 2005-102821   | 20030729    |
| CN 101172977  | A    | 20080507          | CN 2007-10169490 | 20030729    |
| ZA 2005000784   | A    | 20060830          | ZA 2005-784      | 20050125    |
| US 20050250777  | A1   | 20051110          | US 2005-522697   | 20050127    |
| US 7351732  | B2   | 20080401          |                  |             |
| MX 2005PA01245  | A    | 20050912          | MX 2005-PA1245   | 20050131    |
| NO 2005001068   | A    | 20050225          | NO 2005-1068     | 20050225    |
| PRIORITY APPLN. INFO.:  |      |                   | ES 2002-1811     | A 20020731  |
|   |      |                   | CN 2003-818339   | A3 20030729 |
|   |      |                   | WO 2003-ES394    | W 20030729  |
| OTHER SOURCE(S):  |      | MARPAT 140:181451 |                  |             |
| GI  |      |                   |                  |             |





I



II

AB Title compds. I [wherein R<sup>1</sup> = H, (CH<sub>2</sub>)<sub>3</sub>, (CH<sub>2</sub>)<sub>4</sub>, CH<sub>2</sub>-S-CH<sub>2</sub>, S-CH<sub>2</sub>-CH<sub>2</sub>; W = N, S; X = (CH<sub>2</sub>)<sub>n</sub>; n = 0 or 1; Z = alk(en/yn)yl; R<sub>2</sub> = H, aryl, ar/alkyl; Y = (CH<sub>2</sub>)<sub>m</sub>; m = 0-2; R = O, CH<sub>2</sub>; R<sub>3</sub> = (un)substituted Ph, naphthyl, tetrahydronaphthyl, furyl, thiophenyl, pyrrolyl, pyridinyl, benzimidazolyl, quinolinyl, isoquinolinyl, chromanyl, etc.] were prepared as agonists of serotonin receptor subtype (5- hydroxytryptamine, 5-HT) 5-HT<sub>1A</sub> and which are hence useful in the treatment of pathol. states for which an agonist of said receptors is indicated. Twenty-one product characterizations and five biol. examples are given. I were prepared by N-alkylations of amines with organic halides in CH<sub>3</sub>CN at 60° for 6-24 h (no specific examples are given). In an in vitro test, II inhibited the forskolin-stimulated adenylate cyclase activity of He-La cells transfected with the human 5HT<sub>1A</sub> receptor with CE<sub>50</sub> = 16.3 nM. In a rat permanent focal ischemic model for middle cerebral artery occlusion, II exhibited a 25% reduction in the infarct volume when administered i.v.. Thus, I are neuroprotective agents used for treatment and prophylaxis of cerebral damage caused by ischemic or traumatic stroke.


IT 658714-55-7P, (±)-2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole 658714-56-8P, (.-.-)-2-[4-[[[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazole 658714-57-9P, (.-.-)-2-[4-[[[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-c]thiazole 658714-58-0P, (±)-3-[4-[[[(Chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine 658714-60-4P, (±)-3-[6-[[[(Chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine 658714-66-0P 658714-67-1P, 3-[4-[2-(Phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine 658714-76-2P 658714-77-3P 658714-78-4P 658714-79-5P 658714-80-8P 658714-81-9P 658714-87-5P 658714-88-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-HT<sub>1A</sub> receptor agonist; preparation of fused heterocycles as 5-HT<sub>1A</sub> receptor agonists)


RN 658714-55-7 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methylamino]butyl]tetrahydro-(CA INDEX NAME)]




RN 658714-56-8 CAPLUS

CN Imidazo[1,5-b]isothiazole-4,6(2H,5H)-dione,  
5-[4-[[3-(4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro- (CA  
INDEX NAME)




RN 658714-57-9 CAPLUS

CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione,  
5-[4-[[3-(4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX  
NAME)




RN 658714-58-0 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[[3-(4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX NAME)




RN 658714-60-4 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[[3-(4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]- (CA INDEX NAME)




RN 658714-66-0 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)




RN 658714-67-1 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)



RN 658714-76-2 CAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,  
2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-77-3 CAPLUS


CN Imidazo[1,5-b]isothiazole-4,6(2H,3aH)-dione,  
5-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-78-4 CAPLUS


CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione,  
6-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-79-5 CAPLUS


CN 2,4-Thiazolidinedione, 3-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-80-8 CAPLUS


CN 2,4-Thiazolidinedione, 3-[5-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-81-9 CAPLUS

CN 2,4-Thiazolidinedione, 3-[6-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 658714-87-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-phenoxylethyl)amino]butyl]-, hydrochloride (1:1), (7aS)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 658714-88-6 CAPLUS

CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxylethyl)amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:388180 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 131:44735  
 TITLE: Preparation of aminoalkylbenzopyrans and analogs as gastric fundus relaxants  
 INVENTOR(S): Wigerinck, Piet Tom Bert Paul; Verschueren, Wim Gaston; Schroyen, Marc Francis Josephine; De Bruyn, Marc Frans Leopold  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.  
 SOURCE: PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE     |
|---|------|----------|------------------|----------|
| WO 9929687  | A1   | 19990617 | WO 1998-EP7771   | 19981127 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW |      |          |                  |          |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |          |
| US 6133277  | A    | 20001017 | US 1998-192686   | 19981116 |
| TW 577886   | B    | 20040301 | TW 1998-87119526 | 19981125 |
| CA 2311669  | A1   | 19990617 | CA 1998-2311669  | 19981127 |
| AU 9924127  | A    | 19990628 | AU 1999-24127    | 19981127 |
| AU 748669   | B2   | 20020606 |                  |          |
| EP 1036073  | A1   | 20000920 | EP 1998-966603   | 19981127 |
| EP 1036073  | B1   | 20060726 |                  |          |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY   |      |          |                  |          |
| BR 9814256  | A    | 20001003 | BR 1998-14256    | 19981127 |
| TR 200001542  | T2   | 20010122 | TR 2000-1542     | 19981127 |
| EE 200000328  | A    | 20010815 | EE 2000-328      | 19981127 |
| EE 4438   | B1   | 20050215 |                  |          |
| JP 2001525407   | T    | 20011211 | JP 2000-524281   | 19981127 |
| HU 2000004492   | A2   | 20020328 | HU 2000-4492     | 19981127 |
| HU 224813   | B1   | 20060228 |                  |          |
| IL 136529   | A    | 20030312 | IL 1998-136529   | 19981127 |
| CN 1155597  | C    | 20040630 | CN 1998-811831   | 19981127 |


|                |    |          |                |          |
|----------------|----|----------|----------------|----------|
| PL 191144      | B1 | 20060331 | PL 1998-341007 | 19981127 |
| AT 334125      | T  | 20060815 | AT 1998-966603 | 19981127 |
| ES 2270541     | T3 | 20070401 | ES 1998-966603 | 19981127 |
| CZ 297895      | B6 | 20070425 | CZ 2000-2018   | 19981127 |
| SK 286268      | B6 | 20080606 | SK 2000-803    | 19981127 |
| ZA 9811081     | A  | 20000622 | ZA 1998-11081  | 19981203 |
| IN 1998DE03657 | A  | 20070302 | IN 1998-DE3657 | 19981203 |
| NO 2000002074  | A  | 20000602 | NO 2000-2074   | 20000419 |
| NO 320727      | B1 | 20060123 |                |          |
| BG 104372      | A  | 20001229 | BG 2000-104372 | 20000424 |
| BG 64624       | B1 | 20050930 |                |          |
| HR 2000000340  | A1 | 20010430 | HR 2000-340    | 20000525 |
| MX 2000PA05524 | A  | 20020225 | MX 2000-PA5524 | 20000605 |
| US 6495547     | B1 | 20021217 | US 2000-641485 | 20000818 |
| HK 1028400     | A1 | 20061110 | HK 2000-107845 | 20001207 |
| US 20030083365 | A1 | 20030501 | US 2002-116590 | 20020403 |
| US 6747045     | B2 | 20040608 |                |          |
| US 20030149093 | A1 | 20030807 | US 2002-235623 | 20020905 |
| US 6852714     | B2 | 20050208 |                |          |

PRIORITY APPLN. INFO.:

|                |    |          |
|----------------|----|----------|
| EP 1997-203808 | A  | 19971205 |
| US 1998-192686 | A3 | 19981116 |
| WO 1998-EP7771 | W  | 19981127 |
| US 2000-641485 | A3 | 20000818 |

OTHER SOURCE(S): MARPAT 131:44735

GI



AB Title compds. [I; R = Z1AR5; R1 = H or 1-3 of halo, alkyl, alkoxy, etc.; R4 = H or alkyl; R5 = N-attached oxodiazacycloalkyl, etc.; R6 = H, alkyl, CH2Ph, alkoxy, carbonyl, etc.; Z = (CH2)1-3, OCH2, CH:CH, CHR3, etc.; R3R4 = bond; Z1 = CO, alkylene, etc.; Z2 = alkylene; Z3 = piperidine-1,n-diyl] were prepared. Thus, (R)-3,4-dihydro-2H-1-benzopyran-2-ylmethyl methanesulfonate (preparation given) was aminated by 1-(3-aminopropyl)tetrahydro-2(1H)-pyrimidinone to give I [R = R1 = H, R4 = CH2NH(CH2)3R5, R5 = 2-oxotetrahydro-1-pyrimidinyl]. Data for biol. activity of I were given.


IT 227298-10-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkylbenzopyrans and analogs as gastric fundus relaxants)

RN 227298-10-4 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:716906 CAPLUS Full-text  
 DOCUMENT NUMBER: 123:97798  
 ORIGINAL REFERENCE NO.: 123:17191a,17194a  
 TITLE: Color photographic material  
 INVENTOR(S): Kaneko, Yutaka; Asatake, Atsushi; Sugino, Motoaki  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 56 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE     |
|------------------------|------|----------|-----------------|----------|
| JP 07128820            | A    | 19950519 | JP 1993-270871  | 19931028 |
| PRIORITY APPLN. INFO.: |      |          | JP 1993-270871  | 19931028 |

GI



AB In the title color photog. material comprising  $\geq 1$  Ag halide emulsion layers on its support,  $\geq 1$  of the emulsion layers contains an acylacetamide yellow coupler such as I (R = H, aliphatic, aromatic, heterocyclic group; R1 = aliphatic, aromatic, heterocyclic group; j = 0-8; R2, X = benzene ring substituent group; k = 0-4; Y = O, NR3, S(O)l; R3 = H, aliphatic, aromatic, or heterocyclic group, sulfonyl, sulfinyl, phosphoryl, acyl, oxycarbonyl, carbamoyl, sulfamoyl; l = 0-2; W = H, group releasable on coupling reaction with oxidized developing agent). This photog. material shows high color d. and low fog level.


IT 165741-47-9 165741-52-6  
 RL: DEV (Device component use); USES (Uses)  
 (yellow photog. coupler)

RN 165741-47-9 CAPLUS

CN Carbamic acid, [2-[3-[[2-chloro-5-[(1-oxotetradecyl)amino]phenyl]amino]-2-




[2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-1,3-dioxopropyl]-2-methyl-1,3-propanediyl]bis-, diphenyl ester (9CI) (CA INDEX NAME)



RN 165741-52-6 CAPLUS

|    |  |
|----|--|
| CN | Carbamic acid, [2-[2-[2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-1,3-dioxo-3-[[5-[(1-oxotetradecyl)amino]-2-propoxyphenyl]amino]propyl]-1,1,2,3,3-pentamethyl-1,3-propanediyl]bis-, diphenyl ether (9CI) (CA INDEX NAME) |
|----|--|



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:v

STN INTERNATIONAL LOGOFF AT 11:53:59 ON 13 JAN 2009